Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4042172 | 0.99 | HTR2A (0.75) | HTR2AHTR2C | |
| SCHEMBL3945602 | 0.94 | HTR2A (0.71) | HTR2AHTR2C | |
| SCHEMBL4040553 | 0.93 | HTR2A (0.75) | HTR2AHTR2C | |
| SCHEMBL4228882 | 0.93 | HTR2A (0.77) | HTR2AHTR2C | |
| SCHEMBL4041233 | 0.91 | HTR2A (0.71) | HTR2AHTR2C | |
| SCHEMBL4037998 | 0.90 | HTR2A (0.73) | HTR2AHTR2C | |
| SCHEMBL4207693 | 0.89 | HTR2A (0.75) | HTR2AHTR2C | |
| SCHEMBL14384635 | 0.89 | HTR2A (0.79) | HTR2AHTR2C | |
| SCHEMBL14385273 | 0.89 | HTR2A (0.76) | HTR2AHTR2C | |
| SCHEMBL4035855 | 0.88 | HTR2A (0.80) | HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2051978-A2 | ACETAMIDE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2009-04-29 | — | — | EP | disclosed |
| WO-2007136875-A2 | ACETAMIDE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007136875-A2 | ACETAMIDE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | disclosed |